4//SEC Filing
Prasad Raju 4
Accession 0001193125-26-007875
CIK 0001674416other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 5:35 PM ET
Size
15.8 KB
Accession
0001193125-26-007875
Insider Transaction Report
Form 4
Prasad Raju
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Shares
2026-01-06$45.15/sh+23,361$1,054,749→ 30,128 total - Exercise/Conversion
Common Shares
2026-01-06$44.31/sh+6,339$280,881→ 36,467 total - Sale
Common Shares
2026-01-06$60.18/sh−18,933$1,139,386→ 17,534 total - Sale
Common Shares
2026-01-06$60.00/sh−5,004$300,240→ 12,530 total - Sale
Common Shares
2026-01-06$60.21/sh−5,763$347,010→ 6,767 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-06−23,361→ 76,639 totalExercise: $45.15Exp: 2033-03-14→ Common Shares (23,361 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-06−6,339→ 7,493 totalExercise: $44.31Exp: 2033-10-13→ Common Shares (6,339 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.4800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.
- [F5]This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001968317
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 5:35 PM ET
- Size
- 15.8 KB